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Edited by Gianni CesareniAbstract The time-speciﬁc requirement of Rho proteins for the
S phase progression of vascular endothelial cells was determined
by reversibly introducing inhibitor proteins with a cell-penetrat-
ing peptide. We found evidence of the reversibility of protein
transduction. The removal of extracellular protein caused the
transduced protein to decay in a manner sensitive to low
temperatures. The time required for a 50% decay correlated with
the protein size. The time-speciﬁc transduction of the inhibitor
proteins uncovered a critical period requiring Rho proteins in the
G1–S transition phase. Reversible protein transduction may thus
be a powerful tool to investigate the time-speciﬁc role of
signaling proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Rho proteins, RhoA, Rac1, and Cdc42, have been shown to
promote cell cycle progression to the S phase [1]. However, it
remains to be determined precisely when they are required for
such S phase progression. It is diﬃcult to examine such a time-
speciﬁc role of Rho proteins by conventional transfection
experiments using constitutive active or dominant negative
mutants, because there is a signiﬁcant time delay in both the
increase and decrease in the level of protein expression. On
the other hand, cell-penetrating peptides such as those found
in human immunodeﬁciency viral Tat protein have been suc-
cessfully utilized to rapidly introduce proteins into living cells
with an intact plasma membrane, thus resulting in signiﬁcant
biological eﬀects [2–5]. Furthermore, the native Tat protein
was shown to exit the cells infected by human immunodeﬁ-
ciency virus and to enter the neighboring uninfected cells [5,6].
The intraperitoneal injection of b-galactosidase conjugated* Corresponding author. Fax: +81-92-642-5552.
E-mail address: khirano@molcar.med.kyushu-u.ac.jp (K. Hirano).
Abbreviations: BAECs, bovine aortic endothelial cells; GFP, green
ﬂuorescence protein; HA, hemagglutinin; PBD, Rac1/Cdc42-binding
domain of p21-activated protein kinase; PTD, protein transduction
domain; RB, RhoA-binding domain of Rho-kinase
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to be delivered to all tissues in mice including brain tissue [7].
We observed that the enhancement of arterial contraction by
introducing a dominant negative mutant of MYPT1, a regu-
latory subunit of smooth muscle myosin phosphatase, was
reversible and reproducible [8]. These observations thus sug-
gested that the intracellularly transduced cell-penetrating
peptide could exit the cells, and therefore protein transduction
could be reversible. The Tat PTD-mediated protein transduc-
tion is thus anticipated to make it possible to examine the time-
speciﬁc role of Rho proteins in the cell cycle progression.
The protein transduction process was initially thought to be
independent of receptor, transporter or endocytosis, and
resistant to a low temperature and ATP-depleted conditions
[3–5,9]. However, there is still controversy regarding the in-
volvement of endocytosis [10–12], energy-dependency [10] and
a speciﬁc ‘‘receptor’’ for entry [13,14]. Moreover, the mecha-
nism for protein transduction could be diﬀerent depending on
the type of cell-penetrating peptides and target cells, as well as
in situations where the peptides were free or conjugated with
cargo [4,5,15]. However, no evidence regarding the reversibility
of protein transduction has yet been obtained, and both the
characteristics and kinetics of protein extrusion remain to be
elucidated.
The present study thus investigated the reversibility of Tat
PTD-mediated protein transduction in the bovine aortic en-
dothelial cells (BAECs) and elucidated some characteristics of
the protein extrusion process. Next, by introducing RhoA- and
Rac1/Cdc42-inhibitory proteins in a time-speciﬁc manner, we,
for the ﬁrst time, determined the critical period of the cell cycle
that requires RhoA and Rac1/Cdc42 for S phase progression.2. Materials and methods
2.1. Construction, expression and puriﬁcation of the recombinant
protein
The vectors used to express PTD-tagged proteins with and without
a hemagglutinin (HA) tag were pTAT, pTATHA, pQE30TAT and
pQE30TATHA [8,16]. pQE30 (Qiagen, Hilden, Germany) was used
to express the control (His)6-tagged proteins without PTD. The
cDNA encoding green ﬂuorescence protein (GFP) was obtained from
pEGFP-N1 (Clontech, Palo Alto, CA, USA). The cDNAs encoding
the RhoA-binding domain (RB) of Rho-kinase (amino acid residues
941–1075 [17]) and the Rac1, Cdc42-binding domain (PBD) ofblished by Elsevier B.V. All rights reserved.
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obtained from the human aorta cDNA library (Clontech). The
cDNA encoding IgG-binding domain of protein A (amino acid res-
idues 23–270 [19]) was obtained from pMALU5 [20]. pMALU5 was
kindly donated by Dr. M. Aizawa (Tokyo Institute of Technology,
Yokohama, Japan). All inserts were obtained by PCR ampliﬁcation
and they were determined to contain no unintended mutation. The
recombinant proteins were expressed and puriﬁed with the Ni2þ-
loaded Hi-Trap chelating column on Akta Prime (Pharmacia, Tokyo,
Japan) as previously described [8]. The protein concentration was
determined with a Coomassie protein assay kit (Pierce, Rockford, IL,
USA).
2.2. Cell culture and analysis of cell cycle progression
The BAECs were cultured as described [21]. The cells were plated at
a conﬂuent density of 25% and the progression of the S phase of the
cell cycle was evaluated by propidium iodide staining as previously
described [22].
2.3. Protocol for protein transduction and extrusion
The cells were mechanically harvested from the culture dishes and
collected in PBS. The cells (at approximately 5 106 cells/ml) were
incubated in PBS containing 1 lM of recombinant proteins for 15 min
at 37 C (transduction step). The cells were then collected by brief
centrifugation and thoroughly washed in ice-cold PBS. The cells were
resuspended in PBS at 5 105 cells/ml and then incubated at the in-
dicated temperature for the indicated period of time (extrusion step).
When the eﬀect of metabolic inhibition was examined, the cells were
incubated for 30 min at 37 C with and without (control) 1 lM of
rotenone and 10 mM of 2-deoxy-D-glucose [23] in the continuous
presence of recombinant proteins after a 15-min transduction step. TheFig. 1. Reversible protein transduction in BAECs. (A) Immunoblot detection
the cells exposed to 1 lM TATHA-RB (25.8 kDa), (His)6-RB (19.0 kDa), TA
The puriﬁed protein (100 ng) was loaded as a positive control. Actin was dete
cell extracts. (B) Time course of decay of TATHA-RB and TATHA-PBD at
min at 37 C. Tubulin was detected by a speciﬁc antibody to validate the eq
proteasome inhibitor MG132 and a low temperature (4 C) on the extrusion o
and without (control) metabolic inhibition (1 lM rotenone+ 10 mM 2-deoxcells were then subjected to the extrusion step with and without met-
abolic inhibition. To remove any possible Tat-tagged proteins attached
to the extracellular surface [10], the cells were equilibrated for 5 min at
4 C after the 15-min transduction step and were then treated with
trypsin (bovine pancreas, Sigma) at 50:1 mass ratio of substrate to
enzyme at 4 C for 10 min. Under this condition, TATHA-RB was
completely proteolyzed in vitro (data not shown). The trypsin diges-
tion was then terminated by adding 10 lM 4-aminido-phenylmethane-
sulfonyl ﬂuoride and by thoroughly washing in ice-cold PBS before
proceeding to further analyses.
2.4. Immunoblot detection of recombinant proteins
The intracellularly transduced proteins were detected as described
[8]. The protein extruded in the bathing buﬀer was recovered and
concentrated by passing the buﬀer through Ni2þ-nitrilo acetate resin
(Qiagen). The recombinant proteins were detected by anti-(His)6 an-
tibody as previously described [8]. The density of bands detected by
anti-(His)6 antibody was normalized by the density of tubulin or actin
in the corresponding samples, and then the relative density at time 0
was assigned to be 100%.
2.5. Flow cytometric analysis of GFP ﬂuorescence
At each time point of the extrusion step, an aliquot of the cell sus-
pension (1.6 105 cells) was directly subjected to ﬂow cytometry, and
GFP ﬂuorescence was analyzed as previously described [24].
2.6. Statistics
All data were expressed as meansS.D. The time required for a 50%
decay was estimated by ﬁtting the decay curve to exponential regres-
sion. The unpaired Student’s t-test evaluated statistical signiﬁcance.
P < 0:05 was considered to be signiﬁcant.of the recombinant proteins with anti-(His)6 antibody in the extract of
THA-PBD (19.6 kDa) and (His)6-PBD (12.8 kDa) for 15 min at 37 C.
cted with naphthol blue black staining to validate equal loading of the
37 C. The cells had been exposed to 1 lM recombinant proteins for 15
ual loading of the cell extracts. (C) The eﬀect of 10 lM cell-permeable
f TATHA-RB and TATHA-PBD. (D) The decay of TATHA-RB with
y-D-glucose). The data are means S.D. (n ¼ 3).
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3.1. Reversible protein transduction in BAECs
The intracellular transduction of RB and PBD was veriﬁed
by immunoblot detection (Fig. 1A) as described [8,25,26]. After
a 15 min incubation, RB and PBD were detected in the extracts
only when they were conjugated with Tat PTD (Fig. 1A; TA-
THA-RB and TATHA-PBD). The subsequent removal of the
recombinant proteins in the bathing buﬀer caused a time-
dependent decrease in the amount of recombinant proteins
detectable in the cell extract (Fig. 1B). The time required for a
50% decline of TATHA-RB (25.8 kDa) and TATHA-PBD
(19.6 kDa) at 37 C was estimated to be 12.9 and 3.9 min, re-
spectively (Fig. 1C). On the other hand, a cell-permeable pro-
teasome inhibitorMG132 (10 lM) had no eﬀect on the decay of
TATHA-RB and TATHA-PBD (Fig. 1C). Lowering the tem-
perature during the extrusion step markedly inhibited the decay
of TATHA-RB (Fig. 1C). However, the metabolic inhibition
with 1 lM rotenone and 10 mM 2-deoxy-D-glucose [23] had no
eﬀect on the decay of TATHA-RB (Fig. 1D).
To rule out any possible involvement of Tag-tagged proteins
attached to the extracellular surface in the observations shown
in Fig. 1 [10], the cells were treated with trypsin after a 15-minFig. 2. Immunoblot analyses of protein transduction and extrusion after tryp
with anti-(His)6 antibody in the extract of the cells exposed to 1 lM TATH
trypsin at 50:1 mass ratio of substrate to trypsin at 4 C for 10 min before ex
positive control. Tubulin was detected to validate equal loading of the cell ext
RB at 37 and 4 C after trypsin treatment. The data for the decay at 37 C w
(n ¼ 3). (C) Immunoblot detection of TATHA-RB and (His)6-RB in the ce
removal of the extracellular proteins following trypsin treatment. Tubulin wtransduction step (Fig. 2). Trypsin treatment reduced the
amount of TATHA-RB in the cell extract to 40% of that seen
without trypsin treatment (Fig. 2A). However, the intracellu-
larly transduced TATHA-RB declined after removal of the
extracellular TATHA-RB with a similar time course to that
seen without trypsin treatment, and the time required for a
50% decline was 13.1 min (Fig. 2B). Lowering the temperature
during the extrusion step markedly inhibited the decay of
TATHA-RB as observed without trypsin treatment (Fig. 1C).
Corresponding to the decrease in intracellular TATHA-RB,
TATHA-RB was detected in the bathing buﬀer (supernatant)
after a 30 min incubation in PBS at 37 C (Fig. 2C).
3.2. Decay of TATHA-GFP in BAECs
The extrusion of the transduced proteins was also examined
with TATHA-GFP (Fig. 3). The cells were ﬁrst exposed to 1
lM TATHA-GFP for 15 min at 37 C and then extracellular
TATHA-GFP was removed. The intensity at the peak of
ﬂuorescence distribution thereafter decreased in a time-
dependent manner at 37 C (Fig. 3A). The time required for a
50% decay of TATHA-GFP (37.3 kDa) was estimated to be
34.8 min at 37 C (Fig. 3B). Lowering the temperature to 4 C
during the extrusion step markedly inhibited the decay of GFPsin treatment. (A) Immunoblot detection of the recombinant proteins
A-RB and (His)6-RB for 15 min at 37 C. The cells were treated with
tracting cellular proteins. The puriﬁed protein (100 ng) was loaded as a
ract. (B) Representative photos and summary of the decay of TATHA-
ithout trypsin treatment are from Fig. 1C. The data are meansS.D.
ll extract and the bathing buﬀer (supernatant) at 0 and 30 min after
as detected to validate equal loading of the cell extract.
Fig. 3. Eﬀect of a low temperature and metabolic inhibition on the decay of GFP in BAECs. (A) A representative histogram of a ﬂow cytometric
analysis of GFP ﬂuorescence at the indicated time after removing extracellular TATHA-GFP at 37 C. The cells had been exposed to 1 lMTATHA-
GFP for 15 min at 37 C. (B) The eﬀect of a low temperature (4 C) and metabolic inhibition (1 lM rotenone+ 10 mM 2-deoxy-D-glucose) on the
decay of GFP ﬂuorescence intensity. The data are means S.D. (n ¼ 3).
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(Fig. 3B). These observations were consistent with those seen
for TATHA-RB and TATHA-PBD (Figs. 1 and 2).
3.3. Correlation between the size of protein and the time
required for a 50% decay
Plotting the time required for a 50% decay against the size of
the protein revealed a positive correlation between them
(Fig. 4). Within the molecular sizes examined (20–40 kDa), the
following linear relationship was obtained:
Time required for a 50% decay ðminÞ
¼ 1:7Molecular mass ðkDaÞ  31:5Fig. 4. Relationship between the molecular mass of the recombinant
protein and the time required for a 50% decay in the amount of the
introduced proteins. The time required for a 50% decay at 37 C of
TATHA-GFP (37.3 kDa), TATHA-RB (25.8 kDa) and TATHA-PBD
(19.6 kDa) was plotted against the molecular mass. The relationship
between the molecular mass (kDa) and time required for a 50% decay
(min) was ﬁtted to the linear regression (R2 ¼ 0:99574).3.4. Time-speciﬁc inhibition of the cell cycle progression by the
reversible transduction of RB and PBD
RB and PBS have been shown to serve as dominant negative
mutants against endogenous RhoA and Rac1/Cdc42, respec-
tively [27]. When BAECs were replated at a conﬂuent density
of 25%, the cells started to enter the S phase after 12 h and
reached the peak of the S phase at 24 h (Fig. 5A). When RB
and PBD conjugated with PTD either with or without HA
were applied at time 0, the S phase progression was concen-
tration-dependently inhibited (Fig. 5B). The removal of Tat
PTD abolished the inhibitory eﬀect ((His)6-RB). The controlproteins, TAT-GFP, TATHA-GFP and TATHA-protein A,
had no eﬀect, except that 100 nM TATHA-GFP showed a
slight inhibition (Fig. 5B).
Fig. 5. A reversible inhibition of the cell cycle progression by RB and PBD in BAECs. (A) The time course of progression to the S phase in the control
cells after replating at a conﬂuent density of 25%. The data are meansS.D. (n ¼ 3). (B) A summary of the concentration-dependent eﬀects of
recombinant proteins on the S phase progression as evaluated at 24 h. The recombinant proteins were applied at time 0. The S phase progression was
expressed as a percentage of that obtained in the control. The data are meansS.D. (n ¼ 3). *, P < 0:05 vs. the control (100%). (C) Time-speciﬁc
eﬀect of 100 nM TAHA-RB and TATHA-PBD on the cell cycle progression as evaluated at 24 h. The cells were exposed to the recombinant proteins
according to the protocol shown in the key. The data are meansS.D. (n ¼ 3).
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RB markedly inhibited the S phase progression (Fig. 5C,
protocols 1–3). When applied at 16 h and 20 h, TATHA-RB
was less eﬀective in inhibiting the S phase progression (Fig. 5C,
protocols 4 and 5). On the other hand, when removed after
16 h, TATHA-RB markedly inhibited the S phase progression
(Fig. 5C, protocols 8 and 9). When removed by 12 h, it was less
eﬀective (Fig. 5C, protocols 6 and 7). In protocols 10–13, the
4-h exposure during 12–16 h was found to most eﬀectively
inhibit S phase progression (Fig. 5C, protocol 12). The similar
but weaker time-speciﬁc inhibition of the S phase progression
was observed with TATHA-PBD. As a result, the period
12–16, corresponding to the G1–S transition phase, was the
most critical period that required the RhoA and Rac1/Cdc42
activity for the S phase progression.4. Discussion
The present study provides biochemical and functional evi-
dence that Tat PTD-mediated protein transduction is reversible,
and that intracellularly transduced proteins are extruded from
the cells when extracellular proteins were removed. First, an
immunoblot analysis detected not only a decline in the amount
of the introduced proteins in the cell extract but also an increase
in the amount of the extracellular proteins. There is a possibility
that the decline of Tat-tagged proteins was merely due to wash-
out of any proteins attached to the extracellular surface but not
due to extrusion of the intracellularly transduced protein [10].
However, this possibility was ruled out by the observations
obtained with the cells treated with trypsin. Second, a ﬂow
cytometric analysis demonstrated that the GFP ﬂuorescence
154 K. Hirano et al. / FEBS Letters 570 (2004) 149–154intensity declined over time after the removal of extracellular
PTD-tagged GFP. Finally, a time-speciﬁc treatment with TA-
THA-RB and TATHA-PBD inhibited the S phase progression
in a time-speciﬁc manner. The reversibility of protein trans-
duction thus suggests that PTD-mediated protein delivery is a
consequence of equilibrium between intracellular and extracel-
lular proteins, which is consistent with a previous report [28]. It
is thus also possible to introduce proteins in a quantitative
manner with Tat PTD-mediated protein transduction.
The extrusion of the transduced proteins was found to be
sensitive to low temperatures. However, it was resistant to
metabolic inhibition and proteasome inhibition. Furthermore,
the kinetics of the extrusion process was dependent on the size
of the molecule. The heparan sulfate proteoglycan was re-
ported to serve as a receptor for entry of Tat PTD [10,14].
Such a receptor is absent on the cytoplasmic surface of the
plasma membrane. Our observations thus suggest that such
extrusion is due to the energy-independent passive diﬀusion
across the plasma membrane as a consequence of the equili-
bration shift toward an outﬂow-dominated state. A low tem-
perature is considered to reduce the membrane ﬂuidity,
thereby impeding protein extrusion.
The precise mechanism of protein uptake mediated by cell-
penetrating peptides still remains to be elucidated. Three
modes of uptake have been proposed at present; a direct
penetration-mediated uptake, an inverted micelle-mediated
uptake and a endocytosis/pinocytosis-mediated uptake [29].
The recent publications suggest that the majority of uptake is
mediated by endocytosis or pinocytosis, followed by a partial
release from the vesicles, although the escape from pinocytosis
was reported to be an ineﬃcient process [10–12,29]. The in-
volvement of vesicle-driven uptake is apparently against the
reversibility of protein transduction. Our ﬁndings thus support
the direct penetration or inverted micelle-driven delivery. Al-
ternatively, the uptake mechanism may diﬀer with cargo and
cell type [4,5,15,29].
Both the time-speciﬁc delivery as well as the quantitative
transduction of proteins are diﬃcult to perform with a con-
ventional transfection of nucleotides and its resulting protein
expression. Our analysis of the eﬀects of RB and PBD on the
cell cycle progression, for the ﬁrst time, revealed that the G1–S
transition phase of the cell cycle is the critical period requiring
RhoA and Rac1/Ccd42 for the S phase progression. Further-
more, the concentrations of RB and PBD that are required for
the cell cycle inhibition were found to correlate to those found
in endogenous proteins [30]. Our functional data thus support
the reversibility and quantitativeness of Tat PTD-mediated
protein transduction. Precisely, how RhoA and Rac1/Cdc42
regulate the cell cycle progression in the G1–S transition phase
still remains to be elucidated.
In conclusion, when performed at 37 C, Tat PTD could
deliver proteins into cells with an intact plasma membrane, in a
rapid, quantitative and reversible manner. The equilibrium
across the plasma membrane thus determines the extent of
protein transduction. The time-speciﬁc delivery of inhibitor
proteins of Rho proteins revealed a critical period requiring
their activity to successfully carry out the S phase progression
in BAECs. The Tat PTD-mediated protein transduction thus
could be a powerful tool to investigate the time-speciﬁc and
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